As Robert F ... evidence generated by Merck and by independent investigators, continues to support the safety and efficacy profiles of our HPV vaccines," Rahway, New Jersey-based Merck said ...

Shares of global pharmaceutical company Merck (NYSE:MRK) fell 11% in the morning session after the company reported mixed fourth-quarter earnings. Its full-year revenue and EPS guidance missed by ...

Chairman and CEO Robert Davis told analysts the pause ... that are not yet immunized,” Davis said. For 2025 Merck, based in , Rahway, New Jersey, expects adjusted earnings to range between ...

RAHWAY, N.J. (AP) — RAHWAY, N.J. (AP) — Merck & Co. (MRK) on Tuesday reported fourth-quarter net income of $3.74 billion. On a per-share basis, the Rahway, New Jersey-based company said it had ...

On Tuesday, Merck & Co Inc (NYSE:MRK) reported fourth-quarter sales of $15.62 billion, up 7% year over year and slightly beating the consensus estimate of $15.49 billion. Excluding the impact of ...

Merck & Co.’s blockbuster vaccine Gardasil has had a roller-coaster ride in China. A post-Covid surge in demand for the cancer-preventing shot quickly deflated last year, to the point the US ...

the successful launch of WINREVAIR and strong performance of our Animal Health business," said Robert Davis, chairman and chief executive officer, Merck. Also Read: RJK Jr.'s Involvement In Merck ...

Merck MRK-0.35%decrease; red down pointing triangle shares tumbled more than 11% Tuesday morning after the drugmaker gave 2025 revenue guidance that fell short of analyst expectations and said it ...

Merck CEO Robert Davis said on an earnings call that Gardasil inventory in China "remains elevated at above normal levels," noting that demand for the shot has not recovered to the level the ...

For 2025 Merck, based in , Rahway, New Jersey, expects adjusted earnings to range between $8.88 and $9.03 per share on $64.1 billion to $65.6 billion in sales. Analysts had been projecting ...

They were also up 5,622% and 7%, respectively, year-over-year. Merck Chairman and CEO Robert Davis contributes the company’s strong performance in 2024 to the demand for its “innovative ...